Edluar is based on Orexo’s sublingual tablet technology and the active substance zolpidem. The product offers treatment for short-term insomnia. Zolpidem is a well-documented substance that has been used in the treatment of insomnia for a long time. The Edluar tablet is placed under the tongue, where it rapidly dissolves and the active ingredient is absorbed through the mucous membrane.

 

Short facts  
Technology Edluar 
Indication Insomnia
Commercial rights Worldwide, Mylan
Partner Mylan
Patent protection

US until 2031, Europe until 2025

Edluar was approved by the US Food and Drug Administration, FDA, in March 2009. In June 2012 Edluar was approved for registration in Europe.